linvoseltamab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antitumor, monoclonal antibodies 5777 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • linvoseltamab
  • linvoseltamab-gcpt
  • lynozyfic
  • REGN5458
Linvoseltamab-gcpt is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro, linvoseltamab-gcpt activated T-cells, caused the release of various proinflammatory cytokines, and resulted in the lysis of multiple myeloma cells. Linvoseltamab-gcpt had anti-tumor activity in mouse models of multiple myeloma.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
April 23, 2025 EMA Regeneron Ireland Designated Activity Company (DAC)
July 2, 2025 FDA RENGENERON PHARMACEUTICALS, INC.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX37 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
FDA PE N0000009267 Increased Cytokine Activity
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000175617 CD3-directed Antibody Interactions
FDA MoA N0000175618 CD3 Receptor Agonists
FDA MoA N0000194165 B Cell Maturation Antigen-directed Antibody Interactions
FDA EPC N0000194166 Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsed or refractory multiple myeloma indication 109989006 DOID:9538




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
T-cell surface glycoprotein CD3 Surface antigen BINDING AGENT EC50 6.81 DRUG LABEL DRUG LABEL
Tumor necrosis factor receptor superfamily member 17 Tumour-associated antigen BINDING AGENT Kd 0.44 DRUG LABEL DRUG LABEL

External reference:

IDSource
2408319-25-3 SECONDARY_CAS_RN
CHEMBL5095373 ChEMBL_ID
C000731817 MESH_SUPPLEMENTAL_RECORD_UI
13305 IUPHAR_LIGAND_ID
4044097 VANDF
4044098 VANDF
C5667182 UMLSCUI
CHEBI:758940 CHEBI
12104 INN_ID
D12222 KEGG_DRUG
396209 MMSL
44236 MMSL
d10292 MMSL
020153 NDDF
M3CPC50MZS UNII
2719416 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LYNOZYFIC HUMAN PRESCRIPTION DRUG LABEL 1 61755-054 INJECTION, SOLUTION, CONCENTRATE 5 mg INTRAVENOUS BLA 30 sections
LYNOZYFIC HUMAN PRESCRIPTION DRUG LABEL 1 61755-056 INJECTION, SOLUTION, CONCENTRATE 200 mg INTRAVENOUS BLA 30 sections